Recent studies have suggested that oral administration of acetylcysteine could prevent the reduction in renal function induced by radiographic contrast agents in patients with chronic renal failure. Our prospective, controlled, open-label study included 100 consecutive patients with baseline serum creatinine > 1.5 mg/dl and intravenous hydratation
who underwent coronary angiography.
Baseline and peak post-procedure serum creatinine levels during the following 46 hours were compared in 50 patients with acetylcysteine (600 mg bid, before and after administration of the contrast agent) and 50 patients without acetylcysteine. The baseline clinical characteristics, creatinine levels (Z.l+/-1.2 YS 1 .a+/-0.4 mgldl) and constrast volume (171+/-72 vs 162+/-63 ml) of the 2 groups were similar. The mean changes in creatinine after 24 and 46 hours were -O.l+/-0.2 and O+/-0.3 mgldl in the acetylcysteine group vs O+/-0.2 and 0~1-0.4 mgidl in the control group (NS) . A contrast-agent-induced renal dysfunctioq, defined as 25% increase in creatinine levels, occurred in 2 patients of the acetylcysteine group and 2 patients of the control group Previous studies have shown that rheolytic thrombectomy results in adenosine release by hemofyzed red blood cells. Adenosine is the proposed agent that causes bradycardia and asystole known to be associated with rheolytic thrombectomy.
Aminophylline
has been shown to block adenosine receptors in cardiac tissue. This retrospective study evaluated whether administration of aminophylline prior to rheolytic throm-be&my prevented bradycardia.
Methods:
The study group consisted of 39 patients presenting with an acute coronary syndrome who were divided into a non-aminophylline group (18 patients) and an aminophylline group (21 patients). Records were reviewed for the frequency of treatment for hemodynamically significant bradycardia.
Results: Of the 18 patients in the non-aminophylline group. temporary pacemakers were prophylactically placed in 11 (61%). Of the other 7 patients, 3 patients required treatment with &opine.
In 21 patients receiving aminophylline. 15 (72%) experienced no dysrhythmiss, 3 (14%) experienced bradycardia not requiring treatment and 3 (14%) experienced bradycardia requiring atropine. Of all 39 patients, 37 were procedural wccesses by TIMI definition (Grade 3 perfusion). one had TIMI 2 flow and only one was left with TIMI 0 flow. Therefore, 14/l 8 non-aminophylline compared with 3/21 aminophylline treated patients received treatment for bradycardia.
Conclusion:
Aminophylline appears to obviate the need for a prophylactic temporaly pacemaker and may become the preferred primary method for prevention of bradycarda during rheolytic thrombectomy. The use of closure devices (CD) to achieve hemostasis after femoral artery access in PCI is steadily increasing. However, the safety information with these devices in the era of triple antipfatelet therapy is limited. We reviewed the prospectively collected data from the TARGET trial, being the largest such PCI dataset using concomitant ASA, clopidogrel and Ilb/llla therapy.
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Triple Antiplatelet Therapy Does Not Increase Femoral
Methods:
Patients randomly received abciximab or tirofiban, along with pre-procedural aspirin and clopidogrel loading. All patients received heparin aiming for an ACT of _> 250 seconds. At the treating physician's discretion, manual compression (MC) or vascular device hemostasis was selected following femoral angiography. Patients receiving MC were to have sheaths removed 2-6 hours post-procedure when the ACT was i 175s or aPTT < 50s.
Results: Of TARGET's 4809 patients, 4736 had femoral access, and 985 of these had a CD (Perclose 46.8%, Angioseal 43.5%, VasoSeal 4.7%, other 5.0%). The two groups were similar regarding most demographic characteristics including age, SBP and weight, but those with MC were more often female, diabetic, and had history of PVD. Patients with CD had a lower ischemic event rate suggesting they were a lower risk cohorl overall. Importantly, there were no differences in major bleeding, minor bleeding or transfusions (Table) . 
CD (n=985)
Conclusion:
In contemporary PCI practice, with appropriate patient selection, CD Can be safely utilized despite aggressive polypharmacy for procedural anticoagulation.
